의료진

스킵네비게이션

본문바로가기
주메뉴바로가기

기타
With 울산대학교병원

기타

의료진

기타의료진

종양내과임현수

진료분야위암, 식도암, 위장관기질종양, 신장암, 방광암

예약하기

진료일정 5월 선택됨 5월 6월

진료일정의 경우, 휴진 및 진료과의 사정으로 변경될 수 있으니 확인 후 내원해주시기 바랍니다.

이전달 다음달

임현수 진료일정표
날짜	1 금	2 토	3 일	4 월	5 화	6 수	7 목	8 금	9 토	10 일	11 월	12 화	13 수	14 목	15 금	16 토	17 일	18 월	19 화	20 수	21 목	22 금	23 토	24 일	25 월	26 화	27 수	28 목	29 금	30 토	31 일
오전				진료		진료		진료			진료		진료		휴진			진료		진료		진료					진료		진료
오후						진료	진료						진료	진료						진료	진료						진료	진료

진료 클리닉 휴진

학력
- 한양대학교 의학과 졸업
- 울산대학교 대학원 의학석사
- 울산대학교 대학원 의학박사
경력
- 서울아산병원 인턴
- 서울아산병원 내과 전공의
- 서울아산병원 종양내과 임상강사
- 울산대학교병원 혈액종양내과 임상조교수
- 울산대학교병원 혈액종양내과 조교수
소속학회
- 대한내과학회
- 대한암학회
- 대한종양내과학회
- 대한항암요법연구회
- 대한위암학회
- 미국임상암학회(American Society of Clinical Oncology)
- 유럽종양내과학회(Euoropean Society of Medical Oncology)

Real-world effectiveness and prognostic factors of platinum rechallenge in advanced urothelial cancer. BMC Cancer. 2025 Dec 26;26(1):185.
Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16). Clin Cancer Res. 2026 Jan 16;32(2):291-299.
Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13). Cancer Res Treat. 2025 Oct 13.
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin. JCO Precis Oncol. 2025 Oct;9:e2500510.
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline). J Gastric Cancer. 2025 Jan;25(1):5-114.
Effectiveness of self-reported management program of cancer patients. Digit Health. 2024 Jul 23;10:20552076241253090.
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06). BMC Cancer. 2024 Feb 23;24(1):252.
Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic. Psychiatry Investig. 2023 Dec;20(12):1204-1210.
Development and pilot study of "Smart Cancer Care": a platform for managing side effects of chemotherapy. BMC Health Serv Res. 2023 Aug 29;23(1):922.
Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study. BMC Med Ethics. 2023 Mar 7;24(1):18.
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. J Gastric Cancer. 2023 Jan;23(1):3-106.
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65.
The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation. BMC Cancer. 2022 Sep 20;22(1):997.
Perceptions of the meaning of life among Korean patients with advanced cancer: A mixed-methods study. Palliat Support Care. 2023 Aug;21(4):658-669.
Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea-A Sarcoma-Specific, Institutional Registry-Based Analysis. Cancer Manag Res. 2021 Nov 24;13:8795-8802.
Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. BMC Palliat Care. 2021 Apr 27;20(1):63.
Unmet needs related to the quality of life of advanced cancer patients in Korea: a qualitative study. BMC Palliat Care. 2021 Apr 13;20(1):58.
Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. Ther Adv Med Oncol. 2021 Mar 19;13:17588359211003053.
Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea. Support Care Cancer. 2021 Sep;29(9):5383-5390.
Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5. Cancer Res Treat. 2021 Oct;53(4):1166-1173.
Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. Cancer Med. 2021 Mar;10(5):1745-1758.
Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. Curr Probl Cancer. 2021 Jun;45(3):100685.
Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. In Vivo. 2020 Mar-Apr;34(2):829-837.
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Ther Adv Med Oncol. 2019 Aug 23;11:1758835919871126.
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Rep. 2018 Dec;51(12):660-665.

울산대학교병원

울산대학교병원 주메뉴

With 울산대학교병원

의료진

종양내과임현수

상세정보

학력

경력

소속학회

논문

언론

영상